Late December 2009, GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, announced that it has received European CE mark approval for the EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity. The CE marking (an acronym for the French “Conformite Europeenne” or European conformity) certifies that a product has met EU requirements for marketing in Europe.

Features and benefits include:

• The EndoBarrier is implanted and removed endoscopically.

• The implantation can be carried out as a day procedure

• The overall metabolic effect that results from the implantation of the device is similar to the complicated Roux-en-Y gastric bypass surgical procedure

• Glycemic control in Type 2 diabetes

• Weight loss

• Procedure is reversible

• Safe alternative to gastric bypass

• Non invasive procedure

• Rapid recovery

• Lower costs

It could be a safe way for those who awaiting surgery to lose weight prior to the surgery.